source
- FAIR Act could boost U.S. rare‑disease trial access and restore biotech leadershipIn a recent BioSpace podcast, host Jennifer C. Smith‑Parker talked with Max Bronstein of Aviva Strategies and Teresa Barnes of PF Warriors about a growing problem: U.S. patients are increasingly un…
- Merck’s antibody impresses with ‘highly competitive’ data in chronic skin diseaseMerck has revealed detailed data for tulisokibart from a mid-stage trial in hidradenitis suppurativa that analysts say could help carve out a place in a crowded market that already includes AbbVie’…